KNSA (Kiniksa Pharmaceuticals, Ltd.) Stock Financials & Earnings | Market Cap Arena

KNSA (Kiniksa Pharmaceuticals, Ltd.) Stock Financials & Earnings | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

Mkt Cap$3B

Healthcare·Biotechnology·🇧🇲 Bermuda·NASDAQ

Revenue (TTM)$678M

Net Income (TTM)$59M

EPS (TTM)$0.75

Free Cash Flow (TTM)$136M

Gross Margin54.6%

Op. Margin11.4%

Net Margin8.7%

FCF Margin20.1%

P/S Ratio (TTM)5.1x

P/E Ratio (TTM)59.1x

YoY Rev Growth+60.1%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$48M	$32M	-$11M
Q2 23	$71M	$49M	-$3M
Q3 23	$67M	$40M	-$11M
Q4 23	$83M	$57M	$81K
Q1 24	$80M	$48M	-$17M
Q2 24	$109M	$66M	-$117K
Q3 24	$112M	$63M	-$10M
Q4 24	$123M	$56M	-$19M
Q1 25	$138M	$76M	$13M
Q2 25	$157M	$86M	$20M
Q3 25	$181M	$97M	$24M
Q4 25	$202M	$111M	$20M

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	14.7x	17.7x
Q2 23	12.4x	15.1x
Q3 23	14.0x	—
Q4 23	12.9x	247.4x
Q1 24	11.5x	402.8x
Q2 24	10.3x	—
Q3 24	9.1x	—
Q4 24	8.2x	—
Q1 25	7.2x	—
Q2 25	6.6x	727.4x
Q3 25	5.8x	97.0x
Q4 25	5.1x	59.1x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$4M	-$4M
Q2 23	-$4M	-$4M
Q3 23	$17M	$17M
Q4 23	$4M	$4M
Q1 24	$4M	$4M
Q2 24	$5M	$5M
Q3 24	-$2M	-$2M
Q4 24	$19M	$19M
Q1 25	$22M	$22M
Q2 25	$28M	$28M
Q3 25	$34M	$33M
Q4 25	$54M	$53M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$24K
Q2 23	$34K
Q3 23	$16K
Q4 23	$56K
Q1 24	$84K
Q2 24	$0
Q3 24	$0
Q4 24	$193K
Q1 25	$99K
Q2 25	$165K
Q3 25	$671K
Q4 25	$633K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+50.2%	+7.3%
Q2 23	+165.0%	+61.0%
Q3 23	-32.4%	+47.9%
Q4 23	+34.8%	+49.2%
Q1 24	+65.2%	+61.9%
Q2 24	+52.0%	+45.7%
Q3 24	+67.4%	+56.3%
Q4 24	+46.9%	+70.2%
Q1 25	+72.5%	+29.2%
Q2 25	+44.3%	+25.6%
Q3 25	+61.2%	+28.7%
Q4 25	+65.0%	+28.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$6M	12.6%
Q2 23	$6M	9.1%
Q3 23	$7M	10.1%
Q4 23	$8M	9.3%
Q1 24	$7M	9.0%
Q2 24	$7M	6.8%
Q3 24	$8M	7.0%
Q4 24	$8M	6.8%
Q1 25	$8M	5.6%
Q2 25	$9M	5.7%
Q3 25	$10M	5.6%
Q4 25	$4M	1.9%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$15M	$28M
Q2 23	$23M	$28M
Q3 23	$17M	$34M
Q4 23	$20M	$37M
Q1 24	$26M	$39M
Q2 24	$24M	$42M
Q3 24	$26M	$46M
Q4 24	$35M	$41M
Q1 25	$19M	$44M
Q2 25	$19M	$47M
Q3 25	$24M	$49M
Q4 25	$35M	$57M

Revenue Segments

Quarter	Collaboration	Product
Q1 23	$6M	$43M
Q2 23	$17M	$54M
Q3 23	$2M	$65M
Q1 24	$973K	$79M
Q2 24	$5M	$103M
Q1 25	—	$138M
Q2 25	—	$157M
Q3 25	—	$181M
Q4 25	—	$202M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$81M	$107M	$187M
Q2 23	$113M	$72M	$185M
Q3 23	$118M	$83M	$201M
Q4 23	$108M	$98M	$206M
Q1 24	$141M	$72M	$214M
Q2 24	$99M	$119M	$219M
Q3 24	$97M	$126M	$224M
Q4 24	$184M	$60M	$244M
Q1 25	$157M	$111M	$268M
Q2 25	$192M	$116M	$308M
Q3 25	$175M	$177M	$352M
Q4 25	$166M	$248M	$414M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	70M	-2.3%
Q2 23	72M	+2.7%
Q3 23	70M	-2.0%
Q4 23	73M	+3.5%
Q1 24	71M	-2.8%
Q2 24	71M	+0.5%
Q3 24	72M	+1.0%
Q4 24	72M	+0.8%
Q1 25	76M	+5.3%
Q2 25	78M	+2.4%
Q3 25	78M	+0.1%
Q4 25	79M	+1.2%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 16	—	—
FY 17	—	—
FY 18	$0	111
FY 19	$0	137
FY 20	$0	168
FY 21	$179K	215
FY 22	$1M	220
FY 23	$910K	297
FY 24	$1M	315
FY 25	$3K	200K